Nina Russell

International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.

Eligix, Inc. develops and distributes medicines. It also offers cellular transplantation and immune therapies to enhance human immune response to cancers and infectious diseases. The company is located in Medford, MA

X-Biotix Therapeutics, Inc. is a biotechnology company focused on the discovery and development, which focuses on the novel small molecule antibiotics that target resistant gram-negative bacteria. The company was founded by Ramani Varanasi in 2016 and is headquartered in Waltham, MA.

Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Linkinvax SA is a French company founded in 2020 by Remi Gaston-Dreyfus, Yves Lévy, André-Jacques Auberton-Hervé, Laurent Hanot, and Mireille Centlivre. The company is based in Paris, France. Linkinvax is developing an innovative protein-based vaccine platform that can accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). The platform is DC targeting-based and can adapt to changes and mutations in the target pathogens. Linkinvax aims to revolutionize vaccine development, particularly for new viruses like Chlamydia and COVID-19. The company is led by André-Jacques Auberton-Hervé, who has been the CEO since 2020.